Selective phosphodiesterase 4 (PDE4) inhibitor. Prepn: S. B. Christensen, WO 9319749; idem, US 5552438 (1993, 1996 both to SmithKline Beecham); idem et al., J. Med. Chem. 41, 821 (1998). Anti-inflammatory activity: M. S. Barnette et al., J. Pharmacol. Exp. Ther. 284, 420 (1998); D. E. Griswold et al., ibid. 705. Pharmacology and therapeutic potential in asthma and chronic obstructive pulmonary disease (COPD): T. J. Torphy et al., Pulm. Pharmacol. Ther. 12, 131-135 (1999). Clinical pharmacokinetics and bioavailability: B. D. Zussman et al., Pharmacotherapy 21, 653 (2001). Clinical trial in COPD: C. H. Compton et al., Lancet 358, 265 (2001). Review of pharmacology and clinical experience: M. A. Giembycz, Expert Opin. Invest. Drugs 10, 1361-1379 (2001).
Antiasthmatic; in treatment of chronic obstructive pulmonary disease.
Antiasthmatic (Nonbronchodilator); Phosphodiesterase Inhibitor